The adaptor-related protein AP2 is a heterotetrameric complex consisting of α, β, μ, and σ subunits, which plays a crucial role in clathrin-mediated endocytosis (CME) and especially in the retrieval of synaptic vesicles at nerve terminals. 1 Interestingly, several stud- ies have elucidated that CME of plasma membrane proteins con- trols the neuronal surface expression of γ- aminobutyric acid and glutamate receptors involved in long-term plastic changes in neuro- transmission and excitatory/inhibitory balance.1 However, only five individuals with AP2M1 mutations associated with neurodevelop - mental disorders have been reported in the literature so far, 1,2 and the few clinical data available suggest that AP2M1 mutations cause a variable phenotype ranging from severe intellectual disability, autism spectrum disorder, and epilepsy to isolated global develop - mental delay (GDD). We report an individual carrying a novel de novo AP2M1 variant with attention- deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, and unexpected hemiplegic migraine (HM).
Mangano, G.D., Antona, V., Santangelo, G., Di Pasquale, G., Colella, J., Salpietro, V., et al. (2025). A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine. HEADACHE, 65(8), 1497-1499 [10.1111/head.15017].
A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine
Mangano G. D.;Antona V.;Mangano G. R.;
2025-01-01
Abstract
The adaptor-related protein AP2 is a heterotetrameric complex consisting of α, β, μ, and σ subunits, which plays a crucial role in clathrin-mediated endocytosis (CME) and especially in the retrieval of synaptic vesicles at nerve terminals. 1 Interestingly, several stud- ies have elucidated that CME of plasma membrane proteins con- trols the neuronal surface expression of γ- aminobutyric acid and glutamate receptors involved in long-term plastic changes in neuro- transmission and excitatory/inhibitory balance.1 However, only five individuals with AP2M1 mutations associated with neurodevelop - mental disorders have been reported in the literature so far, 1,2 and the few clinical data available suggest that AP2M1 mutations cause a variable phenotype ranging from severe intellectual disability, autism spectrum disorder, and epilepsy to isolated global develop - mental delay (GDD). We report an individual carrying a novel de novo AP2M1 variant with attention- deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, and unexpected hemiplegic migraine (HM).| File | Dimensione | Formato | |
|---|---|---|---|
|
Headache - 2025 - Mangano - A novel de novo AP2M1 variant in a patient with attention‐deficit hyperactivity disorder .pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
150.11 kB
Formato
Adobe PDF
|
150.11 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


